Business Wire

IonQ Unveils Its First Quantum Computer in Europe, Online Now at a Record #AQ36

5.12.2024 14:05:00 CET | Business Wire | Press release

Share

IonQ’s quantum computer Forte Enterprise has achieved the record-breaking milestone of #AQ36In partnership with QuantumBasel, IonQ Forte Enterprise will provide European Enterprise Customers, Industries, government entities, and research institutes with local access to IonQ’s most powerful quantum systemsIonQ has opened its First European Innovation Center at the uptownBasel campus in Arlesheim, Switzerland

IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the delivery of IonQ Forte Enterprise to its first European Innovation Center at the uptownBasel campus in Arlesheim, Switzerland. Achieved in partnership with QuantumBasel, this major milestone marks the first datacenter-ready quantum computer IonQ has delivered that will operate outside the United States and the first quantum system for commercial use in Switzerland.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205805000/en/

null

IonQ European Innovation Center - Arlesheim, Switzerland (Photo: Business Wire)

Forte Enterprise is now online servicing compute jobs while performing at a record algorithmic qubit count of #AQ36, which is significantly more powerful than the promised #AQ35. With each additional #AQ, the useful computational space for running quantum algorithms doubles. A system with #AQ36 is capable of considering more than 68 billion different possibilities simultaneously. With this milestone, IonQ once again leads the industry in delivering production-ready systems to customers.

“The successful commissioning of Forte Enterprise in Europe – on schedule and at an even higher performance level than announced previously – demonstrates IonQ’s commitment to driving global quantum adoption through technological leadership and operational excellence,” said Peter Chapman, CEO and President of IonQ. “Achieving #AQ36 is a significant leap forward, opening new possibilities for applications including logistics, finance, pharmaceuticals, chemistry and artificial intelligence.”

“Offering the state-of-the-art Forte Enterprise quantum computing platform to our ecosystem will accelerate the development of quantum applications across a range of fields,” said Damir Bogdan, CEO of QuantumBasel. “By collaborating with IonQ, we’re positioning the uptownBasel campus as a leader in quantum innovation, fostering breakthroughs that address real-world challenges.”

IonQ’s next generation commercial quantum systems such as Forte Enterprise are optimized for data center environments, sporting a rack-mounted form factor, low energy profile, and minimal environmental isolation requirements.

Building on a History of Excellence

Today’s IonQ Forte Enterprise system commissioning represents the culmination of IonQ’s engineering innovation, operational excellence, and enterprise-grade production capabilities.

“This milestone reflects the hard work and ingenuity of teams across IonQ and QuantumBasel,” said Dr. Dave Mehuys, VP of Production Engineering. “We aligned our system build with on-site datacenter construction and IonQ’s manufacturing and production teams leveraged their decades of expertise to bring this groundbreaking system online faster than anticipated.”

Pioneering a New Era of Computing

IonQ’s record-breaking achievement of #AQ36 signals the company’s dedication and success in advancing quantum performance. Forte Enterprise expands the potential for driving groundbreaking research in areas such as quantum chemistry and machine learning.

“IonQ’s ability to deliver Forte Enterprise with #AQ36 reflects our growing capabilities to execute on our mission to drive significant quantum advancements globally,” said Dr. Dean Kassmann, Senior Vice President of Engineering and Technology at IonQ. “Each step we take demonstrates our commitment to bringing quantum computing from the lab to practical, impactful, and commercial uses.”

A Quantum Leap for Europe and Beyond

IonQ’s first European Innovation Center will allow the company to service its European customers out of its QuantumBasel location and to drive research and development of next generation quantum applications in Europe.

As part of its partnership with IonQ, QuantumBasel will offer its ecosystem– including enterprises, research institutes, startups, and universities – direct access to the #AQ36 Forte Enterprise system.

With datacenters now in the Washington, D.C., Seattle, and Basel, Switzerland areas, IonQ has firmly established a global data center footprint, reinforcing its position as a leader in quantum technology.

To learn more about IonQ’s latest innovations, visit www.ionq.com.

About IonQ

IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.

About QuantumBasel

QuantumBasel is a competence center for quantum computing and AI and drives access to commercial quantum computing to foster innovation. QuantumBasel places particular emphasis on technological neutrality and is Switzerland’s first commercial quantum computing hub, providing access to hardware from IBM, D-Wave and IonQ. QuantumBasel’s team of quantum and data scientists trains and supports companies, conducts projects in quantum computing and AI, and collaborates closely with universities and academic institutions. Through an internationally connected ecosystem, QuantumBasel provides access to advanced know-how and technologies, enabling companies in industrial production, logistics, finance, energy, life sciences, and start-ups to achieve innovations they cannot develop independently. www.quantumbasel.com

IonQ Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the terms “adoption,” “advancing,” “advancements,” “collaborating,” “commitment,” “demonstrates,” “development,” “groundbreaking” “milestone,” “next generation,” “optimized,” “potential,” “significant leap forward,” “state-of-the-art,” “will,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the company’s technology driving commercial quantum advantage in the future, the timing of delivering to customers IonQ Forte Enterprise systems, the planned increase to the footprint of the uptownBasel campus in Arlesheim, Switzerland, the company’s ability to establish public-private partnerships, the ability for third parties to implement IonQ’s offerings to increase their quantum computing capabilities, access to IonQ’s quantum computers, the ability to test and execute quantum applications on IonQ’s quantum computers, the opportunity to test and optimize novel quantum-enhanced algorithms for computational challenges on IonQ’s quantum computers; the problems that can be solved by IonQ’s quantum computers, the advantages of IonQ's approach to the manufacturing of IonQ’s systems, IonQ’s quantum computing capabilities and plans, and the scalability and reliability of IonQ’s quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: changes in the competitive industries in which IonQ operates; the ability of IonQ to protect its intellectual property; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, technical roadmap, and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers; or market adoption of quantum computing solutions and IonQ’s products, services and solutions. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241205805000/en/

null
null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye